Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $577.02MP/E –Yield –
Aclaris Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Aclaris Therapeutics's enterprise value was $436.24M on Nov 11, 2026, against $139.41M a year earlier. Over the last 5 years it ranged from -$125.05M to $878.79M, with a median of $300.47M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $436.24M | +174.5% |
| 2025 | Dec 31, 2025 | $158.91M | +4177.1% |
| 2024 | Dec 31, 2024 | $3.72M | – |
| 2023 | Dec 29, 2023 | -$112.64M | -114.0% |
| 2022 | Dec 30, 2022 | $802.10M | +24.0% |
| 2021 | Dec 31, 2021 | $646.64M | +190.7% |
| 2020 | Dec 31, 2020 | $222.47M | – |
| 2019 | Dec 31, 2019 | -$13.22M | -114.0% |
| 2018 | Dec 31, 2018 | $94.75M | -82.2% |
| 2017 | Dec 29, 2017 | $532.54M | +7.1% |
| 2016 | Dec 30, 2016 | $497.41M | +1315.0% |
| 2015 | Dec 31, 2015 | $35.15M | – |
See a number that looks wrong?